CINECA IRIS Institutional Research Information System

PELLEGRINI, CAROLINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.091
AS - Asia 3.674
EU - Europa 3.223
SA - Sud America 553
Continente sconosciuto - Info sul continente non disponibili 398
AF - Africa 198
OC - Oceania 18
Totale 16.155
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.890
IT - Italia 1.525
SG - Singapore 1.263
CN - Cina 959
HK - Hong Kong 571
BR - Brasile 456
SE - Svezia 307
VN - Vietnam 307
DE - Germania 263
FI - Finlandia 173
GB - Regno Unito 164
BG - Bulgaria 162
FR - Francia 148
RU - Federazione Russa 130
CA - Canada 111
JP - Giappone 109
IN - India 106
AT - Austria 80
NL - Olanda 68
TR - Turchia 68
CI - Costa d'Avorio 65
PL - Polonia 52
MX - Messico 47
KR - Corea 37
SN - Senegal 35
AR - Argentina 33
BD - Bangladesh 32
IQ - Iraq 31
UA - Ucraina 31
PK - Pakistan 29
CH - Svizzera 26
IR - Iran 22
ZA - Sudafrica 22
ID - Indonesia 19
PH - Filippine 17
UZ - Uzbekistan 17
AU - Australia 16
EC - Ecuador 16
MA - Marocco 16
CZ - Repubblica Ceca 15
SA - Arabia Saudita 15
BE - Belgio 14
VE - Venezuela 14
CO - Colombia 13
KE - Kenya 11
LT - Lituania 10
DZ - Algeria 9
ES - Italia 9
EG - Egitto 8
IE - Irlanda 8
JM - Giamaica 8
MY - Malesia 8
NG - Nigeria 8
AE - Emirati Arabi Uniti 7
PT - Portogallo 7
PY - Paraguay 7
TW - Taiwan 7
AZ - Azerbaigian 6
JO - Giordania 6
LB - Libano 6
TN - Tunisia 6
TT - Trinidad e Tobago 6
HU - Ungheria 5
NO - Norvegia 5
PS - Palestinian Territory 5
UY - Uruguay 5
AL - Albania 4
CL - Cile 4
CR - Costa Rica 4
DO - Repubblica Dominicana 4
ET - Etiopia 4
NI - Nicaragua 4
PA - Panama 4
AO - Angola 3
DK - Danimarca 3
GD - Grenada 3
GH - Ghana 3
GR - Grecia 3
GT - Guatemala 3
KG - Kirghizistan 3
KZ - Kazakistan 3
MO - Macao, regione amministrativa speciale della Cina 3
PE - Perù 3
RO - Romania 3
SV - El Salvador 3
TH - Thailandia 3
BH - Bahrain 2
BJ - Benin 2
GE - Georgia 2
IL - Israele 2
LV - Lettonia 2
MK - Macedonia 2
NP - Nepal 2
OM - Oman 2
QA - Qatar 2
UG - Uganda 2
BB - Barbados 1
BO - Bolivia 1
BS - Bahamas 1
BY - Bielorussia 1
Totale 15.742
Salva come PNG Salva come JPEG
Città #
Ashburn 866
Singapore 687
Dallas 647
San Jose 568
Hong Kong 552
Fairfield 481
Santa Clara 421
Woodbridge 329
Chandler 272
Houston 235
Shanghai 209
Seattle 203
Milan 191
Beijing 176
New York 176
Wilmington 170
Cambridge 168
Sofia 160
Serra 156
Council Bluffs 147
Los Angeles 146
Pisa 143
Ann Arbor 139
Boardman 139
Florence 96
Munich 94
Tokyo 88
Rome 84
Princeton 78
Atlanta 68
Helsinki 68
Ho Chi Minh City 68
Abidjan 65
Lauterbourg 65
Lawrence 59
London 56
Hanoi 54
Vienna 53
Hefei 51
Frankfurt am Main 49
Dong Ket 48
Medford 48
Turku 48
Bremen 46
Lucca 44
Chicago 43
Lappeenranta 42
Ottawa 42
Des Moines 40
Redondo Beach 39
São Paulo 38
Buffalo 36
Dakar 35
Istanbul 33
Montignoso 31
Seoul 31
Naples 29
Warsaw 29
Montreal 28
Ogden 27
Dearborn 26
Nanjing 24
Phoenix 23
Bologna 22
Nuremberg 22
Redwood City 22
Livorno 21
Chennai 19
Pistoia 18
Toronto 18
Zurich 18
Brooklyn 17
Rio de Janeiro 17
Washington 17
Tashkent 16
Baltimore 15
Turin 15
Amsterdam 14
Fuzhou 14
San Diego 14
Guangzhou 13
Kent 13
Manchester 13
Marseille 13
Memphis 13
Poplar 13
Brussels 12
Columbus 12
San Francisco 12
Shenzhen 12
Baghdad 11
Brno 11
Da Nang 11
Johannesburg 11
Nairobi 11
Padova 11
Palermo 11
Paris 11
Belo Horizonte 10
Brasília 10
Totale 9.840
Salva come PNG Salva come JPEG
Nome #
Dietary Supplement, Containing the Dry Extract of Curcumin, Emblica and Cassia, Counteracts Intestinal Inflammation and Enteric Dysmotility Associated with Obesity 351
Enteric glial NLRP3 inflammasome contributes to gut mucosal barrier alterations in a mouse model of diet-induced obesity 318
Protective effects of Saccharomyces boulardii CNCM I-745 Against Nonsteroidal anti-inflammatory drug-induced intestinal injury 301
Opioid receptors beyond pain control: The role in cancer pathology and the debated importance of their pharmacological modulation 289
Evaluation of the beneficial effects of a GABA-based product containing Melissa officinalis on post-inflammatory irritable bowel syndrome: a preclinical study 278
Histochemical Detection of Collagen Fibers by Sirius Red/Fast Green Is More Sensitive than van Gieson or Sirius Red Alone in Normal and Inflamed Rat Colon 277
Protective Role of Flavonoids Against Colonic Motor Dysfunctions Associated with High Fat Diet-Induced Obesity 273
Palmitoylethanolamide Counteracts Enteric Inflammation and Bowel Motor Dysfunctions in a Mouse Model of Alzheimer’s Disease 272
COMPOSTI INIBITORI DELL’INFLAMMASOMA NLRP3 E LORO USO 270
The pharmacological blockade of P2X4 receptor as a viable approach to manage visceral pain in a rat model of colitis 252
Adenosine signaling as target in cardiovascular pharmacology 252
Colonic dysmotility associated with high-fat diet-induced obesity: Role of enteric glia 234
Pathophysiology of NSAID-associated intestinal lesions in the rat: Luminal bacteria and mucosal inflammation as targets for prevention 230
Assessment of serum cytokines predicts clinical and endoscopic outcomes to vedolizumab in ulcerative colitis patients 229
A Comparative Study on the Efficacy of NLRP3 Inflammasome Signaling Inhibitors in a Pre-clinical Model of Bowel Inflammation 226
Microbiota-gut-brain axis in health and disease: Is NLRP3 inflammasome at the crossroads of microbiota-gut-brain communications? 221
Dietary Supplementation with the Probiotic SF68 Reinforces Intestinal Epithelial Barrier in Obese Mice by Improving Butyrate Bioavailability 218
Prodromal Intestinal Events in Alzheimer's Disease (AD): Colonic Dysmotility and Inflammation Are Associated with Enteric AD-Related Protein Deposition 217
Colonic motor dysfunctions in a mouse model of high-fat diet-induced obesity: an involvement of A2B adenosine receptors 216
The flavonoid compound apigenin prevents colonic inflammation and motor dysfunctions associated with high fat diet-induced obesity 209
Small bowel protection against NSAID-injury in rats: Effect of rifaximin, a poorly absorbed, GI targeted, antibiotic 209
Preclinical development of fa5, a novel amp-activated protein kinase (Ampk) activator as an innovative drug for the management of bowel inflammation 206
NLRP3 at the crossroads between immune/inflammatory responses and enteric neuroplastic remodelling in a mouse model of diet-induced obesity 201
USP7 and USP47 deubiquitinases regulate NLRP3 inflammasome activation 198
NSAID-induced enteropathy: are the currently available selective COX-2 inhibitors all the same? 194
Enteric protective effects of the combination Bifidobacterium longum and lactoferrin in a rat model of diclofenac-induced intestinal injury. 193
Small Intestine Neuromuscular Dysfunctions and Neurogliopathy in a Mouse Model of High-Fat Diet-Induced Obesity: Involvement of Toll-Like Receptor 4 191
Luteolin Prevents Cardiometabolic Alterations and Vascular Dysfunction in Mice With HFD-Induced Obesity 191
Use of Saccharomyces boulardii CNCM I-745 as therapeutic strategy for prevention of nonsteroidal anti-inflammatory drug-induced intestinal injury 189
Glial A2B Adenosine Receptors Modulate Abnormal Tachykininergic Responses and Prevent Enteric Inflammation Associated with High Fat Diet-Induced Obesity 188
AMPK Activators as Novel Drug Candidates for the Treatment of Inflammatory Bowel Diseases 187
Alteration of colonic excitatory tachykininergic motility and enteric inflammation following dopaminergic nigrostriatal neurodegeneration 185
The AMPK enzyme-complex: from the regulation of cellular energy homeostasis to a possible new molecular target in the management of chronic inflammatory disorders 185
Canonical and Non-Canonical Activation of NLRP3 Inflammasome at the Crossroad between Immune Tolerance and Intestinal Inflammation 181
Donepezil improves vascular function in a mouse model of Alzheimer's disease 181
Enteric α-synuclein impairs intestinal epithelial barrier through caspase-1-inflammasome signaling in Parkinson’s disease before brain pathology 180
Interplay between colonic inflammation and tachykininergic pathways in the onset of colonic dysmotility in a mouse model of diet-induced obesity 179
Mechanisms underlying the non-anticoagulant effects of apixaban and dabigatran on the integrity of intestinal mucosa: a comparative pre-clinical study. 178
Protective effects of the combination Bifidobacterium longum plus lactoferrin against NSAID-induced enteropathy 178
Intestinal histomorphological and molecular alterations in patients with Parkinson's disease 176
The intestinal barrier in disorders of the central nervous system 173
High Levels of β-Amyloid, Tau, and Phospho-Tau in Red Blood Cells as Biomarkers of Neuropathology in Senescence-Accelerated Mouse 173
Involvement of the P2X7 purinergic receptor in colonic motor dysfunction associated with bowel inflammation in rats 172
Managing Obesity and Related Comorbidities: A Potential Pharmacological Target in the Adenosine System? 170
The role of purinergic pathways in the pathophysiology of gut diseases: pharmacological modulation and potential therapeutic applications 168
Intestinal dysfunction in Parkinson's disease: Lessons learned from translational studies and experimental models 167
Enteric Glia and Brain Astroglia: Complex Communication in Health and Disease along the Gut-Brain Axis 166
Deepening the Mechanisms of Visceral Pain Persistence: An Evaluation of the Gut-Spinal Cord Relationship 160
Enteric dysfunctions in experimental Parkinson's disease: alterations of excitatory cholinergic neurotransmission regulating colonic motility in rats 157
Adenosine signaling in the tumor microenvironment 157
Effects of L-DOPA/benserazide co-treatment on colonic excitatory cholinergic motility and enteric inflammation following dopaminergic nigrostriatal neurodegeneration 156
Anti-inflammatory effect of a novel locally acting A2A receptor agonist in a rat model of oxazolone-induced colitis. 151
Rifaximin Displays a Protective Activity in Experimental Enteropathy Induced by Indomethacin in Rats. 151
Constipation, deficit in colon contractions and alpha-synuclein inclusions within the colon precede motor abnormalities and neurodegeneration in the central nervous system in a mouse model of alpha-synucleinopathy 150
Interplay among gut microbiota, intestinal mucosal barrier and enteric neuro-immune system: a common path to neurodegenerative diseases? 149
Role of cyclooxygenase pathways in bowel fibrotic remodelling in a murine model of experimental colitis 147
Development of an Acrylate Derivative Targeting the NLRP3 Inflammasome for the Treatment of Inflammatory Bowel Disease 147
Differential Impact of Weight Loss and Glycemic Control on Inflammasome Signaling 147
From the intestinal mucosal barrier to the enteric neuromuscular compartment: an integrated overview on the morphological changes in Parkinson's disease 146
Pathological remodelling of colonic wall following dopaminergic nigrostriatal neurodegeneration 144
The Anti-Inflammatory and Pain-Relieving Effects of AR170, an Adenosine A3 Receptor Agonist, in a Rat Model of Colitis 143
Dietary flavonoids as a potential intervention to improve redox balance in obesity and related co-morbidities: a review 138
Lactiplantibacillus plantarum HEAL9 attenuates cognitive impairment and progression of Alzheimer's disease and related bowel symptoms in SAMP8 mice by modulating microbiota-gut-inflammasome-brain axis 136
Prokineticin-2 Is Highly Expressed in Colonic Mucosa of Early Parkinson's Disease Patients 135
P2X7 receptor-dependent tuning of gut epithelial responses to infection 134
Role of the A(2B) receptor-adenosine deaminase complex in colonic dysmotility associated with bowel inflammation in rat 130
Development of an adipocyte differentiation protocol using 3T3-L1 cells for the investigation of the browning process: identification of the PPAR-γ agonist rosiglitazone as a browning reference drug 128
Ectopic Lymphoid Organs and Immune-Mediated Diseases: Molecular Basis for Pharmacological Approaches 127
Author Correction: Enteric α-synuclein impairs intestinal epithelial barrier through caspase-1-inflammasome signaling in Parkinson’s disease before brain pathology (npj Parkinson's Disease, (2022), 8, 1, (9), 10.1038/s41531-021-00263-x) 127
Intestinal epithelial barrier and neuromuscular compartment in health and disease 123
Gut-directed therapy in Parkinson’s disease 118
Phytochemicals as Novel Therapeutic Strategies for NLRP3 Inflammasome-Related Neurological, Metabolic, and Inflammatory Diseases 117
Role of proteinase-activated receptors 1 and 2 in nonsteroidal anti-inflammatory drug enteropathy 117
Enteric glia at the crossroads between intestinal immune system and epithelial barrier: Implications for parkinson disease 117
Prolonged treatment with probiotics mitigates intestinal dysfunction and enteric Alzheimer's-related pathology in senescence-accelerated mice 115
null 114
Approaches for designing and discovering purinergic drugs for gastrointestinal diseases 114
Pathological Remodeling of the Gut Barrier as a Prodromal Event of High-Fat Diet-Induced Obesity 113
NLRP3 inflammasome in cardiovascular diseases: Pathophysiological and pharmacological implications 113
Neuronal regulation of intestinal immune functions in health and disease 111
Gastric motor dysfunctions in Parkinson's disease: Current pre-clinical evidence 106
Pharmacological modulation of P2X4 in inflammatory bowel diseases: the way towards novel therapeutics? 104
Glomerular hyperfiltration in morbid obesity: Role of the inflammasome signalling 103
null 103
- Medicament for preventing or treating irritable bowel syndrome or inflammatory bowel diseases 102
The adenosine system at the crossroads of intestinal inflammation and neoplasia 101
α-Synuclein in Parkinson's Disease: From Bench to Bedside 98
Inflammatory Bowel Diseases: It's Time for the Adenosine System 92
NKG2A and COVID-19: another brick in the wall 87
Neuromuscular Function Abnormalities 80
Editorial: IBD Management—Novel Targets and Therapeutic Perspectives 79
LRRK2 is reduced in Parkinson’s disease gut 79
The administration of Enterococcus faecium SF68 counteracts compositional shifts in the gut microbiota of diet-induced obese mice 77
Velusetrag rescues GI dysfunction, gut inflammation and dysbiosis in a mouse model of Parkinson's disease 75
LRRK2 expression in normal and pathologic human gut and in rodent enteric neural cell lines 64
Gastrointestinal dysmotility in rodent models of Parkinson’s disease 59
Are LRRK2 mysteries lurking in the gut? 58
Editorial: Reviews in neuropharmacology 2023: microbiota gut-brain axis, therapeutic insights for neurodegenerative diseases 47
How leaky is the gut in Parkinson’s disease? 44
Special Issue “Drugs in Inflammatory Bowel Diseases” 39
Totale 16.121
Salva come PNG Salva come JPEG
Categoria #
all - tutte 47.602
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 47.602
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022724 0 16 18 25 146 113 41 36 62 41 49 177
2022/20231.195 120 151 89 93 114 138 24 106 220 41 78 21
2023/20241.326 78 105 162 98 184 218 49 80 79 49 111 113
2024/20253.443 56 114 72 192 266 413 328 142 382 403 371 704
2025/20264.983 296 480 705 436 472 334 714 259 333 564 180 210
2026/20271.488 229 1.259 0 0 0 0 0 0 0 0 0 0
Totale 16.155